國家衛生研究院 NHRI:Item 3990099045/4903
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 854924      在线人数 : 873
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/4903


    题名: Bacteremia due to extended-spectrum-beta-lactamase-producing enterobacter cloacae: Role of carbapenem therapy
    其它题名: Bacteremia due to extended-spectrum-β-lactamase-producing enterobacter cloacae: role of carbapenem therapy
    作者: Lee, CC;Lee, NY;Yan, JJ;Lee, HC;Chen, PL;Chang, CM;Wu, CJ;Ko, NY;Wang, LR;Chi, CH;Ko, WC
    贡献者: Division of Infectious Diseases
    摘要: Enterobacter cloacae is one of important nosocomial pathogens. However, few studies specifically dealing with clinical characteristics and outcome of extended-spectrum beta-lactamase (ESBL)-producing E. cloacae infections have been published. During an eight-year period in a medical center, of 610 E. cloacae bacteremic isolates, 138 (22.6 %) with ESBL genes were designated as the ESBL group; and 120 (19.6 %) with cefotaxime-nonsusceptible without ESBL phenotype and genes as the control group. Of the former isolates, 133 (96.3%) had blaSHV-12, three (2.1%) blaCTX-M3, and two (1.4%) both blaSHV-12 and blaCTX-M3. After exclusion of age <18 year, there were 206 adults with E. cloacae bacteremia, 121 patients in the ESBL group and 85 in the control group. More episodes of hospital-onset and polymicrobial bacteremia, increased severity of illness, more bacteremic onset in intensive care units (ICUs), and longer stay in the hospital and ICU after bacteremic onset, were noted in the ESBL group. However, the crude and sepsis-related mortality rates in two groups were similar. Of the ESBL group, the in-hospital sepsis-related mortality rate of patients definitively treated by a carbapenem was lower than that of those by non-carbapenem ss-lactams (5/53, 9.4% vs. 13/44, 29.5%; P=0.01), though the difference was not significant in the hierarchical multivariate analysis (P=0.46). Among 62 patients with follow-up blood cultures within 14 days of bacteremic onset, breakthrough bacteremia was more common in those treated by a non-carbapenem beta-lactam agent than those treated by a carbapenem (18/31, 58.0% vs. 3/31, 9.6%; P<0.001). Thus, carbapenem therapy for ESBL-producing E. cloacae bacteremia may provide therapeutic benefits.
    日期: 2010-09
    關聯: Antimicrobial Agents and Chemotherapy. 2010 Sep;54(9):3551-3556.
    Link to: http://dx.doi.org/10.1128/aac.00055-10
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0066-4804&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000281005900003
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=77956129671
    显示于类别:[其他] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    PUB20547798.pdf314KbAdobe PDF844检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈